Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 87,006 shares at $36.14 ($3.1M) on 2025-02-19, disclosed to the SEC on 2025-02-19.
Scheduled sale ($3.1M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.90 | 23,996 | $837K | 26.9% |
| 2 | $36.14 | 31,467 | $1.1M | 36.5% |
| 3 | $36.14 | 31,467 | $1.1M | 36.5% |
| 4 | $36.56 | 76 | $3K | 0.1% |
| Total | $35.80 avg | 87,006 | $3.1M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |